Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma

PURPOSE: To determine the clinical and biologic effects of bevacizumab, an anti–vascular endothelial growth factor (VEGF) monoclonal antibody, in unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Adults with organ-confined HCC, Eastern Cooperative Oncology Group performance status o...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Siegel, Abby B., Cohen, Emil I., Ocean, Allyson, Lehrer, Deborah, Goldenberg, Alec, Knox, Jennifer J., Chen, Helen, Clark-Garvey, Sean, Weinberg, Alan, Mandeli, John, Christos, Paul, Mazumdar, Madhu, Popa, Elizabeta, Brown, Robert S., Rafii, Shahin, Schwartz, Jonathan D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2008
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3635806/
https://ncbi.nlm.nih.gov/pubmed/18565886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2007.15.9947
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi